GlassScriptPhysician profile
Amanda J Galloway
NPI 1396764148
$6,621.79
in general payments reported to CMS, 2019-2025
41 companies · $3,036 in 2025
The $3,036 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.35 · 2022: $47.48 · 2023: $651 · 2024: $2,843 · 2025: $3,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478 · Education: $51.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,477.74 |
| Education | $51.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $781.54 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $595.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $534.91 | 2023-2025 | Omnipod |
| Amgen INC. | $434.86 | 2023-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $427.97 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $361.00 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $320.06 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.99 | 2021-2025 | Jardiance |
| Dexcom, INC. | $266.33 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $243.95 | 2023-2025 | |
| Beta Bionics, INC. | $178.42 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $152.25 | 2023-2025 | Licart, Tirosint, Flector |
| Acella Pharmaceuticals, LLC | $143.18 | 2023-2025 | NP Thyroid 60 |
| Corcept Therapeutics | $134.40 | 2024-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $130.07 | 2023-2025 | Unithroid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $113.95 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $113.95 | 2024-2025 | Xyosted |
| Tandem Diabetes Care, INC. | $111.19 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $108.54 | 2024-2025 | |
| Medtronic, INC. | $107.41 | 2023-2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $92.11 | 2025 | |
| Glaxosmithkline, LLC. | $87.48 | 2021-2025 | Shingrix, Arexvy |
| Recordati_rare_diseases_inc. | $82.76 | 2024-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $80.38 | 2025 | Yorvipath |
| Mannkind Corporation | $74.79 | 2023-2025 | Afrezza |
| Sequel Med Tech, LLC | $72.55 | 2025 | Twiist |
| Nevro Corp. | $68.82 | 2023-2024 | Senza |
| Currax Pharmaceuticals LLC | $65.94 | 2023-2024 | Nexletol, Contrave |
| Cequr Corporation | $63.78 | 2024-2025 | Cequr Simplicity |
| Vivus LLC | $49.03 | 2023-2024 | Qsymia |
| Avvisto Therapeutics, LLC | $45.00 | 2025 | Cycloset |
| Halozyme INC | $42.78 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $38.73 | 2025 | |
| Astellas Pharma US INC | $38.40 | 2024-2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $34.56 | 2024 | Strensiq |
| Kyowa Kirin, INC. | $25.81 | 2024 | Crysvita |
| Radius Health, INC. | $24.20 | 2025 | Tymlos |
| Pfizer INC. | $22.49 | 2022 | |
| Alvogen INC | $21.23 | 2023 | Teriparatide |
| Ascensia Diabetes Care US INC. | $19.53 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.51 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.